AI English summary of an SEC filing — figures as filed

The company said its Board increased the size of the Board from 10 to 11 and appointed Dr. Joon Lee as a new director, and both actions took effect on June 18, 2025.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Jun 23, 2025Period of report Jun 18, 2025Summary published (UTC) Oct 14, 2026

Key points

AI summary

The company said its Board increased the size of the Board from 10 to 11 and appointed Dr. Joon Lee as a new director, and both actions took effect on June 18, 2025.
The company said Dr. Lee will serve on the Science and Technology Committee and the Compensation and Talent Committee of the Board. The press release introduced him as an independent director.
The company said Dr. Lee will be eligible to receive an annual cash retainer and a director equity grant under the company's non-employee director compensation policy. It said the details are set out in the Definitive Proxy Statement on Schedule 14A filed on August 9, 2024.
The company said Dr. Lee is CEO of Emory Healthcare, Inc. and has more than 25 years of experience at UPMC. It said there were no arrangements or understandings relating to his selection, and no transactions reportable under Item 404(a).

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Medtronic Expands Board to 11 Seats from 10 and Appoints Dr. Joon Lee

The company said its Board increased the size of the Board from 10 to 11 and appointed Dr. Joon Lee as a new director, and both actions took effect on June 18, 2025.

Source · Based on the filing body and exhibits

Lee Named to Science and Technology and Compensation and Talent Committees

The company said Dr. Lee will serve on the Science and Technology Committee and the Compensation and Talent Committee of the Board. The press release introduced him as an independent director.

Source · Based on the filing body and exhibits

Annual Cash Retainer and Equity Grant Under Director Pay Policy

The company said Dr. Lee will be eligible to receive an annual cash retainer and a director equity grant under the company's non-employee director compensation policy. It said the details are set out in the Definitive Proxy Statement on Schedule 14A filed on August 9, 2024.

Source · Based on the filing body and exhibits

Lee's Background and No Related Arrangements

The company said Dr. Lee is CEO of Emory Healthcare, Inc. and has more than 25 years of experience at UPMC. It said there were no arrangements or understandings relating to his selection, and no transactions reportable under Item 404(a).

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.